Yvonne Naughton
Head of Investor Relations

Hello, everyone, and welcome to UCB's Capital Markets Call to discuss the results of BE BOLD in psoriatic arthritis, which was presented on Saturday at the EULAR Conference in London. My name is Yvonne Naughton, and I lead the Investor Relations team here at UCB.

This call is intended for capital market participants only. For any other participants, we ask that you please now disconnect. This event is being recorded and is covered by the disclaimer and safe harbor statement as stated on Slide 2 of the presentation. Following this event, the presentation will be available for download on the Investor Relations section of our website.

Hosting our call today is UCB's Executive Vice President and Head of Patient Evidence, Emmanuel Caeymaex. Joining Emmanuel to present BE BOLD is Professor Iain McInnes, Vice Principal and Head of the College of Medical, Veterinary and Life Sciences at the University of Glasgow. We are also joined by Professor Joe Merola, expert in psoriatic disease and dermatologist and rheumatologist.

In conversation with Emmanuel, Joe will provide his perspective on prescribing practices and how he expects these to be impacted by BE BOLD data, after which Emmanuel will turn the call over to the operator for the Q&A. This call focuses on BE BOLD clinical data and perspectives on its impact on prescribing practices. We will not discuss any access, commercial